Will MSN Push On With US Generic Entresto Launch By The Week’s End?
Novartis Petitions Court Claiming ‘MSN Has Threatened Imminent Launch’
Novartis has been spooked by the potential for MSN Laboratories to launch its generic version of the originator’s $3bn Entresto (sacubitril/valsartan) heart failure brand, filing an emergency motion in an appeals court in Washington DC just days ahead of the proposed expiry of one of Entresto’s US patents.
